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REPLY
We appreciate the interest by Dr. Rassi in our recent study on the
role of angiotensin-converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARBs) in diabetes prevention (1).
We agree that lifestyle modifications that increase physical activity
and minimize abdominal obesity are the most rational and cost-
effective strategies for preventing type 2 diabetes. Despite this
knowledge, compliance with a prescription for daily exercise and
lasting weight loss proves difficult for many people; the epidemic of
diabetes continues to escalate. Thus, safe pharmacologic ap-
proaches for preventing this disease will probably be relevant and
important for many individuals.
Screening for new-onset diabetes using the American Diabetes
Association criteria of a fasting plasma glucose of 126 mg/dl at
two different visits in patients with no diabetes at the time of
enrollment is a valid initial test to identify this disease at its early
stages and prevent its chronic sequelae. However, the use of data
from relatively short-term studies to calculate a number-needed-
to-treat (NNT) can be misleading, as the risk of diabetes accrues
over decades or, indeed, a lifetime.
Insulin resistance is a common pathophysiologic disturbance
that plays a causal role in both hypertension and type 2 diabetes. It
also results in overactivity of the rennin-angiotensin-aldosterone
system leading to hypertrophy and stiffening of smooth muscles in
the arterial wall and left ventricle. Angiotensin-converting enzyme
inhibitors and ARBs have a proven efficacy for improving outcomes
in insulin-resistant conditions, such as hypertension, coronary heart
disease (CHD), and congestive heart failure, and they are the most
effective antihypertensive agents for regressing smooth muscle hyper-
trophy commonly seen in these conditions (2). The fact that they also
reduce the risk of new-onset diabetes is just one more reason to choose
them for these established indications over other antihypertensive
agents that worsen insulin sensitivity, such as traditional beta-blockers
and diuretics (3).
Metabolic syndrome is a more robust marker for risk of type 2
diabetes and CHD events (4). If the NNT with an ACE inhibitor
or ARB to prevent the development of new-onset diabetes in these
patients is to be calculated, it will be substantially lower than that
found in populations from our study, who were obviously at a
lower risk. Therefore, as we have advocated, targeting high-risk
prediabetic individuals for use of an ACE inhibitor or ARB
therapy will increase the cost-effectiveness of these medications.
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Long-Term Bosentan
Treatment in Children With
Pulmonary Arterial Hypertension
One of the core principles of scientific research is to provide full
details of the experimental methods for replication in further study
or clinical practice. As with many published studies (1), Rosenz-
weig et al. (2) failed to provide details of the drug formulation in
their report. Bosentan is currently only commercially available in
tablet form, and the dosing used in their study appears to be
multiples of halved/quartered tablets. It is widely recognized that
splitting tablets causes significant dosing inaccuracy, even when
commercially available tablet cutters are used (3,4). Furthermore,
many children are unable to swallow whole tablets (5), and
crushing the tablets can impair drug absorption (6). Rosenzweig
et al. (2) do not report how their patients took the dose (whether
or not it was swallowed whole).
If the published report does not detail the drug formulation and
method of administration, the reliability of any findings is ques-
tionable as the methods cannot be repeated accurately. If tablets
were cut in half/quartered and crushed, both the amount of drug
administered and its absorption are questionable, bringing the
validity of the results into doubt.
In their report, Rosenzweig et al. (2) cite a pharmacokinetic
study (7) on the dosing of bosentan in pediatric patients that also
fails to give formulation and administration details and whose
lowest dose is 31.25 mg as opposed to 15.6 mg in Rosenzweig et al.
(2). Bosentan may well be a useful agent in the treatment of
pulmonary arterial hypertension in children; surely it is now time
that a pediatric liquid formulation be developed, the efficacy and
dose optimization of which can be addressed in a well-conducted
prospective clinical trial.
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REPLY
We agree with Dr. Standing that a pediatric formulation of
bosentan is needed. The pharmaceutical development of a pediat-
ric formulation, in the form of an orodispersible tablet with a
flexible dosage of 8 to 32 mg, is currently undergoing clinical
evaluation in children in Europe and in the U.S.
However, during the course of development and validation of
the pediatric formulation, the current adult formulation of bosen-
tan was used to begin evaluation of the pharmacokinetics and
safety of bosentan in children (1). We acknowledge that we do not
describe in detail in our study (2) the technical aspects associated
with cutting the adult tablets for the treatment of children.
However, several studies have shown the adult formulation is
suitable to this situation:
1. The active bosentan substance is uniformly spread throughout
the bosentan tablet.
2. Seventy-five percent of the tablet weight is drug substance,
thereby limiting the possibility of nonuniformity of the med-
ication dose.
3. The weight of halved tablets, split with a commercially
available tablet cutter, was within European and U.S. Phar-
macopeia specifications (Actelion, personal communication,
2001). In addition, dissolution rates were measured and found
to be similar for both whole and halved tablets.
Therefore, the use of split tablets was considered appropriate for
conducting a pharmacokinetic study (1). Quartered tablets were
not tested at that time. In our study (2), we followed the sponsor’s
recommendations of using a commercially available cutter to split
the tablets, with no crushing of halved/quartered tablets, and direct
oral administration.
Whereas the pharmaceutical development of the pediatric
formulation of bosentan was ongoing, we treated children with
symptomatic pulmonary arterial hypertension (PAH) at our clinics
with the adult bosentan formulation following the sponsor’s
recommendation for dosing in children at that time (i.e., based on
a conservative extrapolation by weight of the recommended adult
dosages). Using this approach, these data demonstrated the safety
and efficacy of bosentan for pediatric PAH. However, we also
agree with Dr. Standing that pediatric dosing needs to be studied
further. We anticipate that the current evaluation of a pediatric
bosentan formulation will lead to optimal bosentan dosing regi-
mens for children with PAH.
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Limitations of Crush Technique
Ge et al. (1) reported the results of a prospective study on long-term
outcomes of “crush technique” (CT) with drug-eluting stents. This
study raises, in our opinion, two main issues.
First, as pointed out by Williams and Abbott in their editorial
(2), this study reports a clearly worse outcome as compared to
studies with “provisional T stenting” (PTS) and serious concerns
about safety profile (4.4% incidence of stent thrombosis). More-
over, the success rate in recrossing the stent struts for final kissing
balloon is not reported in the study. Because 36% of patients did
not undergo final kissing balloon postdilation, we may assume that,
at least in some of them, it was not possible to recross the stent
struts. This is an important limitation as any further therapy of
side-branch restenosis in “unrecrossable” patients (40% incidence)
becomes virtually impossible by means of percutaneous coronary
intervention (PCI). From this perspective, PTS appears also to be
superior as a second stent is needed in only 15% to 33% of cases,
and final kissing balloon is possible in 95% of cases (3).
Additionally, in case of side-branch restenosis it is always possible
to perform additional PCI. Taken together these limitations may
“crush” down the clinical role of CT, a conclusion not clearly
underlined by the investigators.
Second, the modest results of CT reported in the study by Ge
et al. (1) are not surprising. In fact, CT results in three drug-
eluting stent (DES) layers crushed on an arterial wall at a site of
high hemodynamic turbulence, with high chances of the stents’
incomplete expansion where the coverage should be maximal. This
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